Dr. Dino PratoEnvita Medical Centers · Founder and CEO at Envita Medical Centers

The Tragic Consequences of Delayed Cancer Treatments

2 Nov 2025 · 1 min

Watch on YouTube

0:51

In this presentation, an experienced precision oncology practitioner (over 25 years in the field) argues that the traditional, pharma‑driven model of cancer drug development creates dangerous delays for patients. Conventional drug approval processes require a single drug to be validated for broad populations, which forces extensive testing of each DNA/RNA transcriptome and results in a 10–15‑year lag before a therapy becomes widely available. The speaker emphasizes that data‑driven, precision‑targeted care is essential now, not in the distant future, and describes his lifelong mission to provide individualized genomic treatment blueprints directly to patients, bypassing the slow conventional pipeline.

Chapters

Every day we see the benefits of precision oncology after two and a half decades of working in this area we know that data matters and precisional care matters in the old model what I call the conventional care before it starts getting to this level of high level precision it's going to take a while and the reason has to do with it's mainly a big pharma driven model with drug design that has to go through not just its approval but it's for the masses so then they have to approve a drug for every single DNA RNA transcriptome it's to take forever and we can't wait forever when you think it takes a drug by the time it gets approved to becoming widely available not just Approved widely available 10 to 15 years nobody can wait that long we need that care now and that's what precision targeting is that's been the mission of my life's work and our team is to get that targeted blueprint to our patients so we can help them.